MoonLake Immunotherapeutics
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
MLTX$12.56-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| (in thousands) | 2026 | 2025 |
| Cash flow from operating activities | ||
| Net loss | $(69,707) | $(40,559) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 845 | 378 |
| Share-based compensation expense | 13,355 | 2,290 |
| Net periodic pension benefit gain (loss) for the qualified pension plan | 11 | (4) |
| Other non-cash items | 422 | 124 |
| Changes in operating assets and liabilities: | ||
| Other receivables | (894) | (146) |
| Operating lease right-of-use assets | (30) | — |
| Prepaid expenses | (10,100) | 273 |
| Other non-current assets | (749) | (1,698) |
| Trade and other payables | (6,173) | 3,013 |
| Operating lease liabilities | (389) | (255) |
| Accrued expenses and other current liabilities | 7,123 | (1,556) |
| Net cash flow used in operating activities | (66,286) | (38,140) |
| Cash flow from investing activities | ||
| Purchase of short-term marketable debt securities | (59,068) | (88,548) |
| Proceeds from maturities of short-term marketable debt securities | 59,166 | 144,829 |
| Purchase of property and equipment | — | (35) |
| Net cash flow provided by investing activities | 98 | 56,246 |
| Cash flow from financing activities | ||
| Proceeds from long-term debt, net of issuance costs | 24,467 | 73,022 |
| Issuance of Class A Ordinary Shares, net of transaction costs | 6,007 | — |
| Proceeds from options exercised under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan | 170 | — |
| Proceeds from options exercised under Employee Stock Option Plan | — | 100 |
| Net cash flow provided by financing activities | 30,644 | 73,122 |
| Effect of movements in exchange rates on cash held | (483) | (88) |
| Net change in cash and cash equivalents | (36,027) | 91,140 |
| Cash and cash equivalents, beginning of period | 334,517 | 180,426 |
| Cash and cash equivalents, end of period | $298,490 | $271,566 |
| Supplementary disclosure of cash flow information: | ||
| Cash paid for interest | $1,819 | $— |
| Non-cash operating lease right-of-use assets obtained in exchange for lease obligations | $567 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.